Potentially important new Alzheimer’s disease research has been presented by US pharma giant Merck & Co (NYSE: MRK) around its drug verubecestat.
Despair and dashed hopes have for so long been the story for Alzheimer’s patients and their families seeking an effective treatment for the cruel disease, and these findings have been described as scientifically significant by independent experts as well as by Merck.
"We look forward to seeing the data from our ongoing Phase III clinical trials"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze